Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8648037 | ABBVIE | Macrocyclic proline derived HCV serine protease inhibitors |
Jan, 2032
(7 years from now) | |
US8937150 | ABBVIE | Anti-viral compounds |
May, 2032
(8 years from now) | |
USRE48923 | ABBVIE | Crystal forms |
May, 2035
(11 years from now) | |
US9321807 | ABBVIE | Crystal forms |
Jun, 2035
(11 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10028937 | ABBVIE | Anti-viral compounds |
Jun, 2030
(6 years from now) | |
US10039754 | ABBVIE | Anti-viral compounds |
Jun, 2030
(6 years from now) | |
US9586978 | ABBVIE | Anti-viral compounds |
Nov, 2030
(6 years from now) | |
US10028937 (Pediatric) | ABBVIE | Anti-viral compounds |
Dec, 2030
(6 years from now) | |
US10039754 (Pediatric) | ABBVIE | Anti-viral compounds |
Dec, 2030
(6 years from now) | |
US9586978 (Pediatric) | ABBVIE | Anti-viral compounds |
May, 2031
(7 years from now) | |
US8648037 (Pediatric) | ABBVIE | Macrocyclic proline derived HCV serine protease inhibitors |
Jul, 2032
(8 years from now) | |
US8937150 (Pediatric) | ABBVIE | Anti-viral compounds |
Nov, 2032
(8 years from now) | |
US11484534 | ABBVIE | Methods for treating HCV |
Mar, 2034
(9 years from now) | |
US10286029 | ABBVIE | Method for treating HCV |
Mar, 2034
(9 years from now) | |
US10286029 (Pediatric) | ABBVIE | Method for treating HCV |
Sep, 2034
(10 years from now) | |
US11484534 (Pediatric) | ABBVIE | Methods for treating HCV |
Sep, 2034
(10 years from now) | |
USRE48923 (Pediatric) | ABBVIE | Crystal forms |
Nov, 2035
(11 years from now) | |
US9321807 (Pediatric) | ABBVIE | Crystal forms |
Dec, 2035
(11 years from now) | |
US11246866 | ABBVIE | Solid pharmaceutical compositions for treating HCV |
Jun, 2036
(12 years from now) | |
US11246866 (Pediatric) | ABBVIE | Solid pharmaceutical compositions for treating HCV |
Dec, 2036
(12 years from now) |
Mavyret is owned by Abbvie.
Mavyret contains Glecaprevir; Pibrentasvir.
Mavyret has a total of 20 drug patents out of which 0 drug patents have expired.
Mavyret was authorised for market use on 10 June, 2021.
Mavyret is available in pellets;oral, tablet;oral dosage forms.
Mavyret can be used as treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in pediatric patients 3 to less than 12 years of age or weighing less than 45 kg, treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg.
Drug patent challenges can be filed against Mavyret from 11 December, 2027.
The generics of Mavyret are possible to be released after 24 December, 2036.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-372) | Jun 10, 2028 |
Pediatric Exclusivity(PED) | Dec 10, 2028 |
New Chemical Entity Exclusivity(NCE) | Aug 03, 2022 |
New Dosing Schedule(D-175) | Sep 26, 2022 |
M(M-259) | Apr 10, 2023 |
Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient
NCE-1 date: 11 December, 2027
Market Authorisation Date: 10 June, 2021
Treatment: Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg; Treatment of chronic hepatitis c virus (hcv) ge...
Dosage: PELLETS;ORAL; TABLET;ORAL